Core Viewpoint - Fujian Haixi New Drug Creation Co., Ltd. successfully listed on the Hong Kong Stock Exchange, marking a significant step for the company in integrating into the international capital market [1] Company Overview - Haixi New Drug is a leading biopharmaceutical company in China, engaged in research, production, and sales, with several innovative drug pipelines [1] - The company operates on a dual-track model combining innovative drugs and generic drugs, focusing on developing globally significant innovative products while steadily advancing generic drugs with substantial market potential [1] Financial Highlights - The global offering was priced at HKD 86.40 per share, with a total issuance scale of approximately HKD 1 billion [1] - The international placement was oversubscribed by 6.3 times, while the Hong Kong public offering saw a staggering 3165 times subscription [1] Strategic Goals - The listing is a crucial initiative for Haixi New Drug to enhance its global brand image and deepen the international strategic layout of its innovative drug products [1] - The company adheres to the development philosophy of "generic drugs support innovation, innovation drives the future," carving out a unique development path over its 13 years of establishment [1]
华泰保荐海西新药成功登陆港交所，开启国际化创新制药新篇章